LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035 by DelveInsight

September 08 14:06 2020
LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035 by DelveInsight

DelveInsight Business Research LLP
DelveInsight’s ‘LAG-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight’s ‘LAG-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report provides the upcoming drugs, market share of this target by indications, forecasted market size of LAG-3-Next Generation Immunotherapy from 2022 to 2035 segmented by seven major markets. This report discusses the recent findings on LAG-3, the role it plays in regulating immune responses in different cell types and the rationale for targeting LAG-3 for effective cancer immunotherapy. The report also covers the current scenario, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2022–2035

View report: https://www.delveinsight.com/report-store/lag-3-next-generation-immunotherapy-competitive-landscape

LAG-3-Next Generation Immunotherapy Understanding

Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the “fifth pillar” of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI which has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 have achieved durable responses in melanoma, renal cancer, Hodgkin’s diseases and lung cancer. However, the success rate of these treatments has been low and a large number of cancers, including colorectal cancer remain largely refractory to CTLA-4 and PD-1 blockade.

Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth. T cells are a type of white blood cell that are part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells. It binds MHCII molecules and modulates T-cell function than either CTLA-4 or PD-1. It acts by regulating CD8+ Tcell expansion in immune reactions that have already been initiated (inhibitory signal) and also, by increasing the Treg cell activity.

LAG-3-Next Generation Immunotherapy Drug Chapters

This segment of the LAG-3-Next Generation Immunotherapy report encloses the detailed analysis of late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the indication-specific clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and awards, advantages and disadvantages of each included drug, and the latest news and press releases.

The major key players such as MacroGenics/Zai Lab, Bristol-Myers Squibb/Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, Regeneron, Xencor, Incyte Biosciences/Agenus, Roche, GlaxoSmithKline, Innovent Biologics (Suzhou) Co. Ltd. and others will significantly increase the market during the forecast period (2022–2035).  

Request for sample pages: https://www.delveinsight.com/sample-request/lag-3-next-generation-immunotherapy-competitive-landscape

Scope of the report

• The report covers the descriptive overview of LAG-3-Next Generation Immunotherapy, explaining its pathophysiology, and current trends in the research.

• Additionally, an all-inclusive account of emerging therapies for LAG-3-Next Generation Immunotherapy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of LAG-3-Next Generation Immunotherapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the LAG-3-Next Generation Immunotherapy market.

Table of contents:

1. Key Insights

2. Executive Summary

3. Competitive Intensity of LAG-3-Next Generation Immunotherapy

4. Market Competition of LAG-3-Next Generation Immunotherapy

5. Technological innovations in LAG-3-Next Generation Immunotherapy

6. Multivariate analysis of the key players in LAG-3-Next Generation Immunotherapy

7. LAG-3-Next Generation Immunotherapy Market Overview at a Glance

7.1. Market Share (%) Distribution of Next-Generation Immunotherapy in 2035

8. Pipeline Therapeutics Analysis (Active Products)

9. Overview: Next Generation Immunotherapy

9.1. Immune Checkpoint Inhibitors

9.2. LAG-3

10. Future Prospects and Challenges in LAG-3-Next Generation Immunotherapy

10.1. Current Clinical Challenges in Immunotherapies

10.2. Future direction of improving response rates of Immunotherapy

11. SWOT Analysis

12. Epidemiology and Forecasting Assumptions

13. Emerging Drugs

13.1. Target indications of LAG-3

13.2. MGD013: MacroGenics/Zai Lab

13.2.1. Drug Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Product Profile

13.3. MBG453: Novartis

13.3.1. Product Description

13.3.2. Other Developmental Activities

13.3.3. Clinical Development

13.3.4. Product Profile

13.4. Relatlimab: Bristol-Myers Squibb/Ono Pharmaceuticals

13.4.1. Product Description

13.4.2. Other Developmental Activities

13.4.3. Clinical Development

13.4.4. Product Profile

13.5. Eftilagimod Alpha (IMP321): Immutep

13.5.1. Drug Description

13.5.2. Clinical Development

13.5.3. Product Profile

13.6. LAG525: Novartis

13.6.1. Product Description

13.6.2. Other Developmental Activities

13.6.3. Clinical Development

13.6.4. Product Profile

13.7. MK-4280: Merck

13.7.1. Product Description

13.7.2. Other Developmental Activities

13.7.3. Clinical Development

13.7.4. Product Profile

13.8. REGN3767: Regeneron

13.8.1. Product Description

13.8.2. Other Developmental Activities

13.8.3. Clinical Development

13.8.4. Product Profile

13.9. FS118: F-star Therapeutics

13.9.1. Product Description

13.9.2. Other Developmental Activities

13.9.3. Clinical Development

13.9.4. Product Profile

13.10. XmAb22841: Xencor

13.10.1. Product Description

13.10.2. Other Developmental Activities

13.10.3. Clinical Development

13.10.4. Product Profile

13.11. INCAGN2385: Incyte Biosciences/Agenus

13.11.1.  Product Description

13.11.2.  Other Developmental Activities

13.11.3.  Clinical Development

13.11.4.  Product Profile

13.12. RO7247669: Roche

13.12.1.  Product Description

13.12.2.  Other Developmental Activities

13.12.3.  Clinical Development

13.12.4.  Product Profile

13.13. TSR-033: GlaxoSmithKline

13.13.1.  Product Description

13.13.2.  Other Developmental Activities

13.13.3.  Clinical Development

13.13.4.  Product Profile

13.14. IBI110: Innovent Biologics (Suzhou) Co. Ltd.

13.14.1.  Product Description

13.14.2.  Other Developmental Activities

13.14.3.  Clinical Development

13.14.4.  Product Profile

14. Assessment by Indication

15. Assessment by Route of Administration

16. Assessment by Stage and Indication

17. Assessment by stage and Route of Administration

18. LAG-3-7 Major Market Analysis

18.1. Market Outlook in the 7MM

18.1.1. Total Market size of LAG-3 in 7MM

18.1.2. Market Size of LAG-3 by indication in 7MM

19. Market Drivers

20. Market Barriers

21. Appendix

21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Download report: https://www.delveinsight.com/sample-request/lag-3-next-generation-immunotherapy-competitive-landscape

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
[email protected]
+919650213330

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

  Categories: